|
1
|
Chen G, Wang Z, Liu XY and Liu FY:
High-level CXCR4 expression correlates with brain-specific
metastasis of non-small cell lung cancer. World J Surg. 35:56–61.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong J, Dai J, Shu Y, et al: Polymorphisms
in EGFR and VEGF contribute to non-small-cell lung cancer survival
in a Chinese population. Carcinogenesis. 31:1080–1086. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang L, Li L, Chen Y and Parkin DM:
Mortality time trends and the incidence and mortality estimation
and projection for lung cancer in China. Zhongguo Fei Ai Za Zhi.
8:274–278. 2005.(In Chinese).
|
|
4
|
Yang L, Parkin DM, Ferlay J, Li L and Chen
Y: Estimates of cancer incidence in China for 2000 and projections
for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250.
2005.PubMed/NCBI
|
|
5
|
Van Dyke AL, Cote ML, Prysak GM, et al:
COX-2/EGFR expression and survival among women with adenocarcinoma
of lung. Carcinogenesis. 29:1781–1787. 2008.PubMed/NCBI
|
|
6
|
Sung B, Jhurani S, Ahn KS, et al:
Zerumbone down-regulates chemokine receptor CXCR4 expression
leading to inhibition of CXCL12-induced invasion of breast and
pancreatic tumor cells. Cancer Res. 68:8938–8944. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rahimi M, George J and Tang C: EGFR
variant-mediated invasion by enhanced CXCR4 expression through
transcriptional and post-translational mechanisms. Int J Cancer.
126:1850–1860. 2010.PubMed/NCBI
|
|
8
|
Tang CH, Tan TW, Fu WM and Yang RS:
Involvement of matrix metalloproteinase-9 in stromal cell-derived
factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis.
29:35–43. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kryczek I, Wei S, Keller E, Liu R and Zou
W: Stromal-derived factor (SDF-1/CXCL2) and human tumor
pathogenesis. Am J Physiol Cell Physiol. 292:C987–C995. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Imai H, Sunaga N, Shimizu Y, et al:
Clinicopathological and therapeutic significance of CXCL12
expression in lung cancer. Int J Immunopathol Pharmacol.
23:153–164. 2010.PubMed/NCBI
|
|
11
|
Andre F, Xia W, Conforti R, et al: CXCR4
expression in early breast cancer and risk of distant recurrence.
Oncologist. 14:1182–1188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chinni RS, Yamamoto H, Dong Z, et al:
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer
cells and promotes growth of metastatic deposit in bone. Mol Cancer
Res. 6:446–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong D and Korz W: Translating an
antagonist of chemokine receptor CXCR4: from bench to bedside. Clin
Cancer Res. 14:7975–7980. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oonakahara K, Matsuyama W, Higashimoto I,
et al: Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved
in the dissemination of NSCLC cells into pleural space. Am J Respir
Cell Mol Biol. 30:671–677. 2004. View Article : Google Scholar
|
|
15
|
Kijima T, Maulik G, Ma PC, et al:
Regulation of cellular proliferation, cytoskeletal function, and
signal transduction through CXCR4 and c-Kit in small cell lung
cancer cells. Cancer Res. 62:6304–6311. 2002.PubMed/NCBI
|
|
16
|
Phillips RJ, Burdick MD, Lutz M, et al:
The stromal derived factor-1/CXCL12-CXC chemokine receptor 4
biological axis in non-small cell lung cancer metastases. Am J
Respir Crit Care Med. 167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martínez-García E, Irigoyen M,
González-Moreno O, et al: Repetitive nicotine exposure leads to a
more malignant and metastasis-prone phenotype of SCLC: a molecular
insight into the importance of quitting smoking during treatment.
Toxicol Sci. 116:467–476. 2010.
|
|
18
|
Su L, Zhong J, Xu H, et al: Differential
expression of CXCR4 is associated with the metastatic potential of
human non-small cell lung cancer cells. Clin Cancer Res.
11:8273–8280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wagner PL, Hyjek E, Vazquez MF, et al:
CXCL12 and CXCR4 in adenocarcinoma of the lung: association with
metastasis and survival. J Thorac Cardiovasc Surg. 137:615–621.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morita S, Okamoto I, Kobayashi K, et al:
Combined survival analysis of prospective clinical trials of
gefitinib for non-small cell lung cancer with EGFR mutation.
Clin Cancer Res. 15:4493–4498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang Z, Zhang J, Zeng X, et al:
Relationship between EGFR expression, copy number and mutation in
lung adenocarcinomas. BMC Cancer. 10:3762010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suzuki S, Dobashi Y, Yamane T, et al:
Protein overexpression and gene amplification of epidermal growth
factor receptor in nonsmall cell lung carcinomas. An
immunohistochemical and fluorescence in situ hybridization study.
Cancer. 103:1265–1273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fischer OM, Hart S, Gschwind A and Ullrich
A: EGFR signal transactivation in cancer cells. Biochem Soc Trans.
31:1203–1208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zaman SN, Resek ME and Robbins SM: Dual
acylation and lipid raft association of Src-family protein tyrosine
kinases are required for SDF-1/CXCL12-mediated chemotaxis in the
Jurkat human T cell lymphoma cell line. J Leukoc Biol.
84:1082–1091. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peipp M, Schneider-Merck T, Dechant M, et
al: Tumor cell killing mechanisms of epidermal growth factor
receptor (EGFR) antibodies are not affected by lung
cancer-associated EGFR kinase mutations. J Immunol. 180:4338–4345.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Porcile C, Bajetto A, Barbieri F, et al:
Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates
ovarian cancer cell growth through the EGF receptor
transactivation. Exp Cell Res. 308:241–253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo Z, Cai S, Fang R, et al: The
synergistic effects of CXCR4 and EGFR on promoting EGF-mediated
metastasis in ovarian cancer cells. Colloids Surf B Biointerfaces.
60:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cabioglu N, Summy J, Miller C, et al:
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu
in breast cancer cells by a novel pathway involving Src kinase
activation. Cancer Res. 65:6493–6497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cabioglu N, Gong Y, Islam R, et al:
Expression of growth factor and chemokine receptors: new insight in
the biology of inflammatory breast cancer. Ann Oncol. 18:1021–1029.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu YG, Jin M, Xu H, et al:
Clinicopathologic significance of HIF-1α, CXCR4, and VEGF
expression in colon cancer. Clin Dev Immunol. 7:5375312010.
|
|
32
|
Spano JP, Andre F, Morat L, et al:
Chemokine receptor CXCR4 and early-stage non-small cell lung
cancer: pattern of expression and correlation with outcome. Ann
Oncol. 15:613–617. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ludovini V, Bellezza G, Pistola L, et al:
High coexpression of both insulin-like growth factor receptor-1
(IGFR-1) and epidermal growth factor receptor (EGFR) is associated
with shorter disease-free survival in resected non-small-cell lung
cancer patients. Ann Oncol. 20:842–849. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Niemiec J, Kolodziejski L and Dyczek S:
EGFR LI and Ki-67 LI are independent prognostic parameters
influencing survivals of surgically treated squamous cell lung
cancer patients. Neoplasma. 52:231–237. 2005.PubMed/NCBI
|
|
35
|
Brabender J, Danenberg KD, Metzger R, et
al: Epidermal growth factor receptor and HER2-neu mRNA expression
in non-small cell lung cancer is correlated with survival. Clin
Cancer Res. 7:1850–1855. 2001.PubMed/NCBI
|
|
36
|
Kanematsu T, Yano S, Uehara H, et al:
Phosphorylation, but not overexpression, of epidermal growth factor
receptor is associated with poor prognosis of non-small cell lung
cancer patients. Oncol Res. 13:289–298. 2003.PubMed/NCBI
|
|
37
|
Meert AP, Martin B, Delmotte P, et al: The
role of EGF-R expression on patient survival in lung cancer: a
systematic review with meta-analysis. Eur Respir J. 20:975–981.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar
|
|
39
|
Grisanti S, Rossi L, Ardighieri C, et al:
CXCR4, EGFR and HER2 expression in patients with high-risk synovial
sarcoma (SS): a clinicopathologic study. J Clin Oncol.
24:95802006.
|
|
40
|
Phillips RJ, Mestas J, Gharaee-Kermani M,
et al: Epidermal growth factor and hypoxia-induced expression of
CXC chemokine receptor 4 on non-small cell lung cancer cells is
regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian
target of rapamycin signaling pathway and activation of hypoxia
inducible factor-1alpha. J Biol Chem. 280:22473–22481. 2005.
|
|
41
|
Li YM, Pan Y, Wei Y, et al: Upregulation
of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer
Cell. 6:459–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
